Initial Discovery

RLBN1001: A highly active drug prototype

The Relburn prototype drug (RLBN1001) was tested in more than 370 patients for non-metabolic uses. Relburn investigators first observed that the drug was associated with rapid induction of marked hypouricemia (i.e., low uric acid). Following up this clinical proof-of-concept, Relburn pursued this lead by identifying the underlying biologic mechanisms that caused this effect. The Company has synthesized libraries of novel compounds to optimize these activities and reduced potential side-effects as a treatment for chronic gout